ClinicalTrials.gov · 小核酸药物临床试验· Novartis Pharmaceuticals·· 2022-01-14AI 评分32
Inclisiran(KJX839)对比安慰剂治疗高胆固醇血症的疗效、安全性、耐受性及生活质量研究
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
AI 导读
一项临床试验评估Inclisiran(KJX839)对比安慰剂,在持续个体化优化降脂治疗基础上,用于高胆固醇血症患者的疗效、安全性、耐受性和生活质量。
来源:ClinicalTrials.gov · 小核酸药物临床试验 · clinicaltrials.gov